Overview

An Open Label Study to Examine the Effects of a High-Fat Meal and Particle Size on the Pharmacokinetics of Orally Administered GSK2118436 in Subjects With BRAF Mutation Positive Tumor

Status:
Completed

Trial end date:
2011-05-13

Target enrollment:

Participant gender:

Summary

The study is designed to evaluate the effects of a high fat meal on the pharmacokinetics of 150 mg of GSK2118436, as well as the effects of particle size on the relative bioavailability of GSK2118436.

Phase:

Phase 1

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

Dabrafenib